bluebird bio, Inc. (BLUE) Position Boosted by Sivik Global Healthcare LLC
Sivik Global Healthcare LLC increased its position in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 16.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,500 shares of the biotechnology company’s stock after buying an additional 2,500 shares during the period. Sivik Global Healthcare LLC’s holdings in bluebird bio were worth $2,404,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also recently modified their holdings of BLUE. QS Investors LLC increased its holdings in bluebird bio by 70.7% during the second quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock worth $127,000 after buying an additional 500 shares during the last quarter. Bank of Montreal Can increased its holdings in shares of bluebird bio by 118.9% in the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock valued at $176,000 after purchasing an additional 911 shares during the last quarter. Turner Investments LLC acquired a new position in shares of bluebird bio in the second quarter valued at $184,000. Biondo Investment Advisors LLC acquired a new position in shares of bluebird bio in the third quarter valued at $203,000. Finally, SG Americas Securities LLC increased its holdings in shares of bluebird bio by 17.9% in the second quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 295 shares during the last quarter.
bluebird bio, Inc. (NASDAQ:BLUE) traded down $0.05 on Thursday, reaching $167.20. 363,700 shares of the company traded hands, compared to its average volume of 835,569. bluebird bio, Inc. has a 1-year low of $56.80 and a 1-year high of $169.60.
bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.68) by ($0.05). The firm had revenue of $7.71 million for the quarter, compared to the consensus estimate of $8.47 million. bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The company’s revenue for the quarter was up 397.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($2.07) EPS. analysts expect that bluebird bio, Inc. will post -6.68 EPS for the current fiscal year.
Several research firms have commented on BLUE. Sanford C. Bernstein began coverage on shares of bluebird bio in a report on Thursday, July 27th. They issued a “market perform” rating and a $109.00 price objective on the stock. BidaskClub upgraded shares of bluebird bio from a “sell” rating to a “hold” rating in a report on Wednesday, August 9th. BMO Capital Markets reiterated a “buy” rating and issued a $108.00 price objective on shares of bluebird bio in a report on Friday, August 4th. Evercore ISI began coverage on shares of bluebird bio in a report on Wednesday, August 16th. They issued an “in-line” rating and a $102.00 price objective on the stock. Finally, Wells Fargo & Company reiterated an “outperform” rating and issued a $158.00 price objective (up from $134.00) on shares of bluebird bio in a report on Tuesday, September 5th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and fourteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $131.05.
In other news, insider Nick Leschly sold 25,667 shares of the company’s stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $115.18, for a total value of $2,956,325.06. Following the completion of the transaction, the insider now owns 339,368 shares of the company’s stock, valued at $39,088,406.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Daniel Lynch sold 500 shares of the company’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $120.00, for a total value of $60,000.00. Following the completion of the transaction, the director now directly owns 3,300 shares of the company’s stock, valued at approximately $396,000. The disclosure for this sale can be found here. Insiders sold 193,168 shares of company stock valued at $25,558,003 in the last ninety days. 3.90% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/11/23/bluebird-bio-inc-blue-position-boosted-by-sivik-global-healthcare-llc.html.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Stock Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related stocks with our FREE daily email newsletter.